Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

Short term headwinds mask long term value opportunity.

Brian Han | 25 August 2026

Geopolitical tensions drive strong profit and dividends for oil refiner.

Mark Taylor | 25 August 2026

Higher costs weigh on profits but stronger sales trends support long term outlook.

Johannes Faul, CFA | 25 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,338.80	54.50	-0.58%
CAC 40	8,439.20	13.81	-0.16%
DAX 40	26,266.14	159.54	0.61%
Dow JONES (US)	53,577.40	160.24	0.30%
FTSE 100	10,886.16	31.84	0.29%
HKSE	25,733.15	222.05	0.87%
NASDAQ	26,151.30	171.11	0.66%
Nikkei 225	66,259.97	403.54	0.61%
NZX 50 Index	14,013.21	20.49	0.15%
S&P 500	7,677.28	24.42	0.32%
S&P/ASX 200	9,127.80	55.90	-0.61%
SSE Composite Index	3,912.30	22.86	0.59%